Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

I believe long-term holders like Adage are giving O'Connor the benefit of the doubt because they believe in the platform. I think they are waiting to see what kind of value and deal O'Connor can deliver on our most advanced program - AXAL. I give it until the end of this year and if he hasn't delivered a significant accretive deal that drives our market cap and price back up to $20-$25 pps I suspect Adage, Broadfin, etc., will step up and pressure for a change in leadership. What we are seeing now is time decay - while we have progressed, our advancements and business plan has not kept pace with the competitive immunotherapy landscape, hence our stock price and market cap have suffered. We need a big deal with Astra Zeneca to get us up to fair value. I having a feeling the wait will be worth it, because frankly O'Connor knows his job is on the line. From the language in the press release today, I think a deal will be announced in the next couple months.